FGF23-neutralizing antibody

An FGF23-neutralizing antibody is a therapeutic modality designed to bind and neutralize fibroblast growth factor 23 (FGF23), a bone-derived hormone that regulates phosphate and vitamin D metabolism. By blocking FGF23, these antibodies increase renal phosphate reabsorption and active vitamin D production, thereby restoring phosphate homeostasis. This class of therapeutics is primarily investigated and used for the treatment of FGF23-related hypophosphatemic diseases, such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). Burosumab is a prominent, FDA-approved example of a fully human monoclonal antibody within this category.

Other names

FGF23 antibodyFGF-23 antibodyFGF 23 antibodyFGF23-AbFGF-23-AbFGF 23-AbFGF23-neutralizing antibodiesFGF-23-neutralizing antibodiesFGF 23-neutralizing antibodiesanti-FGF23 antibodyanti-FGF-23 antibodyanti-FGF 23 antibodyanti-FGF23 monoclonal antibodyanti-FGF-23 monoclonal antibodyanti-FGF 23 monoclonal antibody